Tumor News and Research

RSS

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity.

8 Sep 2010

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

DiaTech Oncology has announced the filing of a patent for Drug Discovery that will provide a new strategy and approach to validate drugs that may be more effective in treating cancer patients

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Complete Genomics Inc., a life sciences company focused on human genome sequencing, today announced a collaboration to identify and validate somatic mutations from 50 pediatric cancer cases from multiple research centers across the United States.

7 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

Research suggests blocking HMGB1 protein can benefit cancer patients

Like some people, cells eat when they are under pressure-but they consume parts of themselves. A multi-function protein helps control this form of cannibalism, according to a study in the September 6 issue of the Journal of Cell Biology.

7 Sep 2010

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.

7 Sep 2010

Researchers to develop new treatment strategy for cancer

Cancer is a difficult disease to treat because it's a personal disease. Each case is unique and based on a combination of environmental and genetic factors. Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells. Many of the side effects experienced by chemotherapy patients are due to the fact that the drugs they are taking aren't selective enough.

7 Sep 2010

Study suggest PET/CT scanning may offer effective breast cancer detection, spread

About one-third of women diagnosed with early-stage breast cancer will have their cancer travel, or metastasize, to other parts of the body, with the bone being the most common site of initial detectable spread. Controversy continues to surround the question of whether CT and bone scans should be standard in evaluating patients for these metastases, or whether integrated PET/CT scanning might be more effective at detecting breast tumors that have reached nearby bones.

4 Sep 2010

Study finds acupuncture can control side effects of cancer treatment

Recent studies have shown that acupuncture can help control a number of symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments.

3 Sep 2010

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers.Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute may have solved the problem by developing a new mathematical model that encompasses all dose levels.

3 Sep 2010

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.

3 Sep 2010

New peer-reviewed study on chemopreventive effects of Protandim

LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.

3 Sep 2010

New study finds additional link between Light At Night and cancer

A new study from the Center for Interdisciplinary Chronobiological Research at the University of Haifa has found an additional link between Light At Night (LAN) and cancer. This research joins a series of earlier studies carried out at the University of Haifa that also established the correlation. "High power light bulbs contribute more to 'environmental light pollution', which the study has shown is a carcinogenic pollution," notes Prof. Abraham Haim, who headed the study.

3 Sep 2010

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Stem cells might be thought of as trunks in the tree of life. All multi-cellular organisms have them, and they can turn into a dazzling variety other cells-kidney, brain, heart or skin, for example. One class, pluripotent stem cells, has the capacity to turn into virtually any cell type in the body, making them a focal point in the development of cell therapies, the conquering of age-old diseases or even regrowing defective body parts.

3 Sep 2010

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.

3 Sep 2010

Tumor News and Research

Silence Therapeutics receives two patents for RNA interference therapeutics

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

Researchers develop new RNA molecule approach to kill cancer cells

Tikcro reports $3.2 million net loss for second-quarter 2010

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Research suggests blocking HMGB1 protein can benefit cancer patients

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Researchers to develop new treatment strategy for cancer

Study suggest PET/CT scanning may offer effective breast cancer detection, spread

Study finds acupuncture can control side effects of cancer treatment

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

New peer-reviewed study on chemopreventive effects of Protandim

New study finds additional link between Light At Night and cancer

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News